Episode summary
Unilever Food Arm to Join McCormick in $44.8 Billion Deal | Bloomberg Intelligence
Bloomberg Intelligence
· · 22 min · Hosts: Paul Sweeney, Scarlet Fu · Guests: Diana Gomes, Sam Fazeli, Mandeep Singh, Hannah Levitt
Summary
Unilever’s food business is being combined with McCormick in a $44.8 billion transaction that creates a larger global seasonings, sauces and condiments company. Diana Gomes says the logic is scale: McCormick brings natural ingredients expertise while Unilever contributes iconic food brands and access to markets McCormick does not currently reach, especially in emerging markets. But she also says investors are reacting to execution risk, because the deal is highly transformative and the new group will need to hit 3% to 5% sales growth by year three after a period of roughly 2% growth.
The episode also covered a wave of healthcare M&A. Eli Lilly’s purchase of Centessa is framed as a small, offensive bolt-on to deepen Lilly’s neuroscience pipeline, while Biogen’s $5.6 billion deal for Apellis fits Christopher Viehbacher’s push to reposition Biogen around immunology and rare diseases.
On tech, Mandeep Singh argued Nvidia’s $2 billion stake in Marvell is not financially meaningful for Nvidia, but it helps extend Nvidia’s ecosystem into custom chips and networking. The segment on JPMorgan Chase focused on the bank’s American Dream Initiative, including $80 billion in small-business lending over 10 years and a plan to expand its small-business client base from 7 million to 10 million.
Key takeaways
- Diana Gomes said the McCormick-Unilever food deal is about scale, market access and combining complementary food capabilities.
- Gomes said McCormick faces high execution risk because the combined business must reach 3% to 5% sales growth by year three.
- Sam Fazeli said Eli Lilly’s Centessa purchase is a bolt-on, not a defensive move, because Lilly is still early in building out its pipeline.
- Fazeli said Biogen’s $5.6 billion Apellis deal fits Christopher Viehbacher’s strategy to tilt the company toward immunology and rare diseases.
- Mandeep Singh said Nvidia’s $2 billion Marvell stake is small for Nvidia but helps spread its GPU ecosystem across custom-chip networks.
- Hannah Levitt said JPMorgan’s American Dream Initiative includes $80 billion in small-business lending over 10 years and a push to add 3 million clients.
Notable quotes
“It is really a combination of bringing the expertise from McCormick's on the natural ingredients side of things with Unilever's foods iconic brands”
“the execution risk is quite high and it's going to be a much more complex organization”
“this feels like it's very offensive rather than defensive”
“Not meaningful for Nvidia. And look, their playbook right now is to create an ecosystem”
“they will be investing 80 billion over 10 years in lending to small businesses”
How the episode opens
Bloomberg Audio Studios podcasts, radio, news. You're listening to the Bloomberg Intelligence podcast. Catch us live weekdays at 10:00 a.m.
Eastern on Apple CarPlay and Android Auto with the Bloomberg Business app. Listen on demand wherever you get your podcasts or watch us live on YouTube. Lots of corporate actions in the marketplace today.
Lots of M&A activity and in fact which good space one of the giants out there Unilever the food business for Unilever is going to join with McCormick in a 44.8 billion dollar transaction. We want to break down this deal. Diana Gomes joins us Bloomberg Intelligence senior equity analyst.
Diana, what's what's the strategy here of these two companies in in in combining their food businesses? Hi, thank you. It is really a combination of bringing the expertise from McCormick's on the natural ingredients side of things with Unilever's foods iconic brands and uh in that protein rich um toppings.
It's it's one of the areas where it makes sense to to combine for that added scale and also reaching markets that McCormick doesn't have access at the moment particularly in emerging markets if we exclude India which is out of the equation in this in this combination. We're seeing shares of McCormick fall 3.7%. What might investors be skeptical of in this combination?
It is a really transformational deal for McCormick. It is quite a sizeable group of assets that they are taking in. So the execution risk is quite high and it's going to be a much more complex organization to to really push through the the sales growth targets that they are envisioning for 3 to 5% in by year three of the combination compared to about 2% where the the companies have been growing to in terms of the these foods business.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- unilever mccormick deal
- biotech m&a
- pharma pipeline buildout
- ai chip and networking platform
- jpmorgan american dream initiative
Companies and tickers mentioned
- UL
- MKC
- LLY
- BIIB
- NVDA
- MRVL
- JPM
- Unilever
- McCormick & Co.
- Eli Lilly & Co.
- Centessa Pharmaceuticals Plc
- Biogen Inc.
- Apellis Pharmaceuticals Inc.
- Nvidia
- Marvell Technology
- JPMorgan Chase
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Anthropic’s IPO Is Said to Be About Six Times Oversubscribed | Bloomberg Intelligence -
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
